information on adjuvant HR+/HER2- breast cancer is not found in the text. The newsletter focuses on other oncology topics. The main part is devoted to the CROWN study, which compared lorlatinib with crizotinib in patients with ALK-positive non-small cell lung cancer (NSCLC). The study demonstrated that lorlatinib significantly reduced the risk of disease progression and death, including intracranial progression, compared with crizotinib. Analysis in patients with existing brain metastases showed a significant reduction in the risk of progression of these metastases. Despite the lack of data on overall survival (OS), lorlatinib is considered a standard treatment and is recommended by international societies such as NCCN and ESMO. The newsletter also contains a case report of a patient with colorectal cancer.